Citations

Clear

9 citation(s) found for "Smith, Joseph A".

Intermediate clinical endpoints as surrogates for overall survival after salvage prostatectomy
Roessler, Navid , Nowicka, Zuzanna , Miszczyk, Marcin , Calleris, Giorgio , Dematteis, Alessandro , Vetterlein, Malte W. , Albisinni, Simone , Poel, H J van der, Cathcart, Paul, Cacciamani, Giovanni , Persad, Raj , Joniau, Steven , Sanchez‐Salas, Rafael , Smith, Joseph A. , Karnes, R. Jeffrey , Ahmed, Mohamed E., Rajwa, Paweł , Shariat, S, Party, the Young Academic Urologists Prostate Cancer Working, Cacciamani, Giovanni E , Gill, Inderbir S , Persad, Raj A , Joniau, Steven , Sanchez-Salas, Rafael , Smith, Joseph A , Karnes, Jeffrey , Rajwa, Pawel , Tilki, Derya , Gontero, Paolo , Marra, Giancarlo , Miszczyk, Marcin , Cathcart, P. , Gill, Inderbir S. , Tilki, Derya , Shariat, Shahrokh F. , Gontero, Paolo , Marra, Giancarlo

Mayo Clinic

BJU International | June 16, 2026 | Volume: 138 | Issue: 3 | Pages: 430-437

10.1111/bju.70352 | PMID 42298374 Get It

Objectives To evaluate biochemical recurrence‐free survival (BRFS) and metastasis‐free survival (MFS) as potential intermediate clinical endpoints (ICEs) for overall survival (OS) in patients undergoing salvage radical prostatectomy (sRP). Patients and Methods Evaluable patients were selected from a retrospective dataset, resulting in a cohort of 879 patients with recurrent, non‐metastatic, hormone‐sensitive prostate cancer treated with sRP at 13 centres. ICE surrogacy was evaluated using a two‐stage approach: (i) at the individual‐patient level by fitting Clayton copula models and estimating Kendall's ( >0.7 indicating a strong association) and (ii) at the centre level, by fitting weighted linear regression of 5‐year OS on 3‐year BRFS and MFS. Results The two‐step analysis included 759 patients for BRFS (366 events) and 476 for MFS (137 events), with median follow‐up of 37 months (95% confidence interval [CI] 36–42 months) and 34 months (95% CI 31–37 months), respectively. At the individual‐patient level, MFS showed a strong association with OS (Kendall's 0.85, 95% CI 0.82–0.88), which was not observed for BRFS (Kendall's 0.63, 95% CI 0.56–0.69). At the centre level, neither 3‐year BRFS ( R 2 = 0.15; slope = 0.34, P = 0.2) nor 3‐year MFS ( R 2 = 0.21; slope = 0.26, P = 0.14) predicted 5‐year OS with sufficient explanatory power. Limitations include the fact that centre‐level analysis was based on single‐arm associations rather than on treatment‐effect surrogacy across arms, and retrospective data collection. Conclusions The BRFS should not be used as a surrogate endpoint in the sRP setting. MFS requires further validation in future prospective studies to confirm its association with OS. Patient‐reported outcomes, such as quality‐of‐life and treatment‐related toxicity, should be considered in parallel with OS.
Salvage Focal Therapy vs Radical Prostatectomy for Localized Radiorecurrent Prostate Cancer
Light, Alexander, Peters, Max, Arya, Manit, Tanaka, Mariana Bertoncelli , Dudderidge, Tim , Emberton, Mark, Grey, Alistair , Hindley, Richard, Laniado, Marc, McCraken, Stuart, Moore, Caroline M., Nigam, Raj , Noureldin, Mohamed , Reddy, Deepika, Virdi, Jaspal, Ahmed, Mohamed, Albisinni, Simone, Cathcart, P. , Joniau, S., Karnes, Robert Jeffrey, Persad, Raj , Rajwa, Paweł, Sanchez-Salas, Rafael, Shariat, Shahrokh F., Smith, Joseph A., Tilki, Derya, Poel, H. G. van der, Calleris, Giorgio , Gontero, P., Marra, Giancarlo, Ahmed, Hashim U., Joniau, Steven , Emberton, Mark , Rajwa, Paweł , Moore, Caroline M. , Joniau, Steven , Rajwa, Pawel , Light, Alexander J. W., Peters, Max , Emara, Amr M. , Moore, Caroline , Orczyk, Clément , Reddy, Deepika , Albisinni, Simone , Karnes, R. Jeffrey , Shariat, Shahrokh F. , Tilki, Derya , Poel, HG van der, Marra, Giancarlo , Ahmed, Hashim U. , Shah, Taimur Tariq

Mayo Clinic

JAMA Oncology | February 12, 2026 | Volume: 12 | Issue: 4 | Pages: 364

10.1001/jamaoncol.2025.6448 | PMID 41678176 Get It

Importance Patients with recurrent prostate cancer after previous radiotherapy typically have poor survival. Those with recurrences prostate confined might be suitable for salvage focal therapy (sFT) or salvage radical prostatectomy (sRP). sFT may offer good cancer control with comparatively less toxic effects, but outcomes beyond 5 years have not been reported, and no study has compared sFT to sRP. Objective To compare cancer control and perioperative complications among patients after sFT vs sRP. Design, Setting, and Participants In this international, multicenter cohort study of matched comparison data, patients undergoing sFT were derived from the prospective UK HIFU (high-intensity focused ultrasound) Evaluation and Treatment and International Cryotherapy Evaluation registries (9 centers; 2006-2024) and the prospective UK Focal Recurrent Assessment and Salvage Treatment cohort study (6 centers; 2014-2018). Patients undergoing sRP were derived from an international retrospective registry (12 centers in 8 countries; 2000-2021). Patients with biopsy-confirmed, localized recurrent prostate cancer postradiotherapy, either external beam radiotherapy, brachytherapy, or both, were included. Data were analyzed from March to July 2025. Exposures sFT using HIFU or cryotherapy vs sRP. Main Outcomes and Measures The primary outcome was cancer-specific survival up to 10 years. Secondary outcomes were overall survival, any perioperative complications (Clavien-Dindo grades 1-5), and major perioperative complications (Clavien-Dindo grades 3-5). Comparisons were made on matched patients following 1:1 cardinality matching within individual multiply-imputed datasets. Matching variables used were radiotherapeutic treatment, years between primary and salvage treatments, European Association of Urology recurrence risk group, and presalvage age, prostate-specific antigen, prostate volume, grade group, T stage, and androgen-deprivation therapy use. Results A total of 923 patients were eligible for matching (419 undergoing sFT and 504 undergoing sRP). Of the patients undergoing sFT, 325 (77.6%) underwent HIFU and the remainder cryotherapy, with 241 (57.5%) treated with quadrant ablation. Of patients treated with sRP, 376 (74.6%) underwent open surgery and the remainder robot-assisted surgery. For sFT vs sRP, 10-year cancer-specific survival was 92% (95% CI, 86%-98%) vs 99% (95% CI, 97%-100%), with no statistically significant difference (restricted mean time lost, −0.09 years; 95% CI, −0.22 to 0.03 years; P = .15; subdistribution hazard ratio, 0.45; 95% CI, 0.05-4.00; P = .47). There was no statistically significant difference in 10-year overall survival (restricted mean survival time, −0.13 years; 95% CI, −0.86 to 0.60 years; P = .72). Undergoing sRP was associated with statistically significant higher odds of any complication (adjusted odds ratio, 24.20; 95% CI, 12.94-45.27; P < .001) and major complication (adjusted odds ratio, 9.31; 95% CI, 3.42-25.36; P < .001). Conclusions and Relevance In this cohort study, sFT and sRP were effective for treating localized radiorecurrent prostate cancer, while sFT was associated with fewer perioperative complications. sFT may provide a favorable therapeutic ratio for many patients with localized radiorecurrent prostate cancer.
Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy
Preißer, Felix , Incesu, Reha‐Baris , Rajwa, Paweł , Chłosta, Marcin , Ahmed, Mohamed E. , Cacciamani, Giovanni , Kretschmer, Alexander , Westhofen, Thilo , Smith, Joseph A. , Graefen, Markus , Calleris, Giorgio , Raskin, Yannic , Joniau, Steven , Sanchez‐Salas, Rafael , Gill, Inderbir S. , Karnes, R. Jeffrey , Cathcart, Paul, Poel, Henk G. van der , Marra, Giancarlo , Tilki, Derya , Ahmed, Mohamed , Cacciamani, Giovanni E , Kretschmer, Alexander , Calleris, Giorgio , Joniau, Steven , Karnes, Robert Jeffrey, Tilki, Derya , Gill, Inderbir S , Rajwa, Pawel , Marra, Giancarlo , Abreu, Andre Luis , Ribeiro, Luis, Gontero, Paolo , Shariat, Shahrokh F.

Mayo Clinic

Cancers | June 9, 2023 | Volume: 15 | Issue: 12 | Pages: 3123

10.3390/cancers15123123 | PMID 37370733 Get It

Background: Lymph node invasion (LNI) represents a poor prognostic factor after primary radical prostatectomy (RP) for prostate cancer (PCa). However, the impact of LNI on oncologic outcomes in salvage radical prostatectomy (SRP) patients is unknown. Objective: To investigate the impact of lymph node dissection (LND) and pathological lymph node status (pNX vs. pN0 vs. pN1) on long-term oncologic outcomes of SRP patients. Patients and methods: Patients who underwent SRP for recurrent PCa between 2000 and 2021 were identified from 12 high-volume centers. Kaplan–Meier analyses and multivariable Cox regression models were used. Endpoints were biochemical recurrence (BCR), overall survival (OS), and cancer-specific survival (CSS). Results: Of 853 SRP patients, 87% (n = 727) underwent LND, and 21% (n = 151) harbored LNI. The median follow-up was 27 months. The mean number of removed lymph nodes was 13 in the LND cohort. At 72 months after SRP, BCR-free survival was 54% vs. 47% vs. 7.2% for patients with pNX vs. pN0 vs. pN1 (p < 0.001), respectively. At 120 months after SRP, OS rates were 89% vs. 81% vs. 41% (p < 0.001), and CSS rates were 94% vs. 96% vs. 82% (p = 0.02) for patients with pNX vs. pN0 vs. pN1, respectively. In multivariable Cox regression analyses, pN1 status was independently associated with BCR (HR: 1.77, p < 0.001) and death (HR: 2.89, p < 0.001). Conclusions: In SRP patients, LNI represents an independent poor prognostic factor. However, the oncologic benefit of LND in SRP remains debatable. These findings underline the need for a cautious LND indication in SRP patients as well as strict postoperative monitoring of SRP patients with LNI.
Evaluation of the In Vitro Activity of the Multikinase Inhibitor BAY 43-9006 (Sorafenib) in Primary Cells from Patients with Myelofibrosis with Myeloid Metaplasia (MMM).
Smith, Joseph Wayne, Powell, Heather L., Tefferi, Ayalew , Loegerling, David, Galvez, Marina, Smith, Joseph W., Kaufmann, Scott H. , Lasho, Terra L. , Mesa, Ruben A.

Mayo Clinic

Blood | April 19, 2020 | Volume: 106 | Issue: 11 | Pages: 4943-4943

10.1182/blood.v106.11.4943.4943 Get It

Abstract Background: Myelofibrosis with myeloid metaplasia (MMM) currently has limited therapeutic options. BAY 43-9006 (sorafenib; Bayer Pharmaceuticals) is a oral multikinase inhibitor with both inhibitory properties against the Raf/ MEK survival pathway and VEGF that are a potential therapeutic targets for the myeloproliferation and apoptotic resistance seen in this disorder. We evaluated the activity of this agent through inhibition of aberrant in vitro myeloid colony growth, as we have previously successfully utilized in this disorder (Leukemia2003;17(5):849). Methods: Peripheral blood mononuclear cells (PBMC) were isolated and plated on the Methocult™ (StemCell Technologies) colony assay media. Dilutions of BAY 43-9006 (0–10 μM) (Phase I trial sustained concentrations of 10 μM (JCO2005;23:965) was added for either a 24 hour incubation, or for 14 days. Myeloid colonies were then quantified according to standards established by the manufacturer. Subsequent assays were performed combining BAY 43-9006 with the pro-apoptotic agents arsenic trioxide (ATO) or adaphostin (ADA) (both at 1.25μM). Finally, immunoblotting was performed on protein extracted from treated primary MMM cells to quantify the downregulation of Mcl-1 (shown to be crucial for the pro-apoptotic effects of BAY 43-9006; Yu et. al. Oncogene 2005). Results: PBMC were isolated from 12 MMM patients and 10 controls (normal n=5, other myeloproliferative (MPD) n=5). Twenty-four hour exposure of cells to the agent was insufficient to suppress aberrant colony growth. Continuous exposure (for 14 days) of the agent led to a median inhibitory concentration-50% (IC50) of 12 μM for MMM (compared to 7.1μM for normals, and 5μM for MPD controls). Although no specificity could be deduced from these latter results, 4 MMM patients had an IC50 of &lt;10μM (range 1.25 to 8.6μM). In contrast, the other 8 patients were quite resistant IC50 of &gt; 10μM (higher than clinically achievable ranges). Subsequently we evaluated whether there might be benefit to use of BAY43-9006 in combination with a pro-apoptotic agent (i.e. ATO or ADA). No significant activity was seen combining ADA with BAY43-9006. When BAY43-9006 was combined with ATO, the median IC 50 for the BAY compound decreased to 2μM (range 1.25 to 16), however there was not a significant increase in colony inhibition over ATO alone. In order to evaluate whether the lack of activity of BAY43-9006 observed in colony formation assays was secondary to a lack of downregulation of the established target Mcl-1, we immunoblotted for Mcl-1 (after in vitro incubation) in a subset of MMM patients. Western blots demonstrated successful downregulation of Mcl-1 by Bay 43-9006 in MMM samples, even in samples with clear in vitro resistance to the drug (i.e. IC50 &gt; 10 μM). Conclusions: The multi-kinase inhibitor BAY43-9006 appears to have minimal activity against primary cells isolated from MMM patients. Although, suppression of aberrant colony growth was noted in a subset of patients the sensitivities would not support specificity when compared to controls. Although BAY 43-9006 was observed to down regulate the anti-apoptotic target Mcl-1, in patient samples, no detectable inhibition of colony formation was observed in 8/12 MMM samples. These preliminary results do not appear to support a clinical trial of BAY 43-9006 in MMM, however combination of this multi-kinase inhibitor with other pro-apoptotic agents should be evaluated.
The Null Effect of Bladder Neck Size on Incontinence Outcomes after Radical Prostatectomy
Tyson, Mark D. , Ark, Jacob , Gregg, Justin R. , Johnsen, Niels V. , Kappa, Stephen F., Lee, Daniel J. , Smith, Joseph A.

Mayo Clinic

Journal of Urology | June 24, 2017 | Volume: 198 | Issue: 6 | Pages: 1404-1408

10.1016/j.juro.2017.06.084 | PMID 28655528 Get It

National Randomized Controlled Trial of Virtual House Calls for People with Parkinson's Disease: Interest and Barriers
Dorsey, E. Ray , Achey, Meredith A. , Beck, Christopher A. , Beran, Denise B., Biglan, Kevin , Boyd, Cynthia M. , Schmidt, Péter , Simone, Richard, Willis, Allison W. , Galifianakis, Nicholas B. , Katz, Maya , Dodenhoff, Kristen A. , Ziman, Nathan, Aldred, Jason , Carter, Julie, Jimenez‐Shahed, Joohi , Hunter, Christine , Spindler, Meredith , Morgan, John C. , McLane, Dedi, Hickey, Patrick , Gauger, Lisa, Richard, Irene Hegeman, Bull, Michael, Mejia, Nicte I. , Bwala, Grace, Nance, Martha , Shih, Ludy C. , Anderson, Lauren , Singer, Carlos , Zadikoff, Cindy , Okon, Natalia, Feigin, Andrew, Ayan, J., Vaughan, Christina , Cooper, Jessica , Webb, S. J., Dhall, Rohit , Hassan, Anhar , Weis, Delana, DeMello, Steven, Smith, Joseph M. , Keenan, H. Tait, Korn, Ryan, Schwarz, Heidi B., Stevenson, E. Anna , Zhu, William , Tanner, Caroline M. , Mari, Zoltan K. , Pahwa, Rajesh , Riggare, Sara S. , Wicks, Paul J , Sharma, Saloni , Jimenez-Shahed, Joohi

Mayo Clinic

Telemedicine and e-Health | February 17, 2016 | Volume: 22 | Issue: 7 | Pages: 590-598

10.1089/tmj.2015.0191 | PMID 26886406 Get It

Background: Delivering specialty care remotely directly into people's homes can enhance access for and improve the healthcare of individuals with chronic conditions. However, evidence supporting this approach is limited. Materials and Methods: Connect.Parkinson is a randomized comparative effectiveness study that compares usual care of individuals with Parkinson's disease in the community with usual care augmented by virtual house calls with a Parkinson's disease specialist from 1 of 18 centers nationally. Individuals in the intervention arm receive four virtual visits from a Parkinson's disease specialist over 1 year via secure, Web-based videoconferencing directly into their homes. All study activities, including recruitment, enrollment, and assessments, are conducted remotely. Here we report on interest, feasibility, and barriers to enrollment in this ongoing study. Results: During recruitment, 11,734 individuals visited the study's Web site, and 927 unique individuals submitted electronic interest forms. Two hundred ten individuals from 18 states enrolled in the study from March 2014 to June 2015, and 195 were randomized. Most participants were white (96%) and college educated (73%). Of the randomized participants, 73% had seen a Parkinson's disease specialist within the previous year. Conclusions: Among individuals with Parkinson's disease, national interest in receiving remote specialty care directly into the home is high. Remote enrollment in this care model is feasible but is likely affected by differential access to the Internet.
Baseline Factors as Predictors of Clinical Progression of Benign Prostatic Hyperplasia in Men Treated With Placebo
Crawford, E. David , Wilson, Shandra, McConnell, John D., Slawin, Kevin M., Lieber, Michael C., Smith, Joseph A. , Meehan, Alan G., Bautista, Oliver, Noble, William R., Kusek, John W., Nyberg, Leroy M., Roehrborn, Claus G.

Mayo Clinic

Journal of Urology | March 3, 2006 | Volume: 175 | Issue: 4 | Pages: 1422-1427

10.1016/s0022-5347(05)00708-1 | PMID 16516013 Get It